In This Issue
Special Series: XYZ of Statistics
Special Series: Big Science, Artificial Intelligence, and Machine Learning
Controversies in Nephrology
Point: Tolvaptan or transplant: why wait? YES
Counterpoint: Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability CON
From the Editors: A tolvaptan skeptic repents
Kidney International (KI) is the official journal of the International Society of Nephrology. Under the editorial leadership of Dr. Pierre Ronco (Paris, France), KI is one of the most cited journals in nephrology and widely regarded as the world's premier journal on the development and consequences of kidney disease.
KI is peer-reviewed and publishes original research in both basic science and clinical medicine. These include the latest clinical studies on emerging developments in renal medicine and the highest level of original research studies in therapy and epidemiology of acute and chronic kidney failure, as well as their translational aspects and genetic basis. In addition relevant aspects of renal physiology, cell biology, biochemistry, pathology, immunology, morphology and new technological developments are reported with the over-all aim of informing the renal researcher and the practicing nephrologist on all aspects of renal research.
The journal reflects the field through critical reviews and original articles, commentaries, editorial updates on recent developments and news features, recommendations and guidelines resulting from expert consensus meetings, aspects of nephrology from the developing world, policy issues, remarkable images, and problem-focused articles for the diagnosis and treatment of renal patients. Kidney International is published monthly.
About the International Society of Nephrology
We strive to advance kidney health worldwide.
Our overarching purpose is to tackle the global burden of acute kidney injury, chronic kidney disease and end-stage kidney disease.
We build capacity with healthcare professionals via granting programs, education and research. We bridge gaps in global kidney care, engaging in a collaborative effort with global partners to improve kidney disease prevention, diagnosis and treatment. By connecting communities, we develop a stronger understanding of how to manage kidney disease.
With thousands of professional members from over 160 countries, we represent a wide international network and an efficient platform for timely scientific exchange, debate and communication between healthcare professionals involved in preventing and treating kidney disease. By collaborating with more than 100 national and regional societies, we reach out to tens of thousands health professionals globally.
2018 Impact Factor is 5.842